Vale Biolabs received €164,000 (CHF 150,000) from Venture Kick. The biotech startup builds human brain organoids and uses automation and predictive AI. It aims to help researchers study brain diseases and test potential treatments.
Use of funds
The funding will support further development of Vale Biolabs' automated platform. The company also plans to expand its human brain organoid models. The work will generate datasets to train and validate the company's AI models.
Founding team
Vale Biolabs was founded by Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano, and Theodoulos Rodosthenous. The founders bring expertise in organoid neurobiology, automation, data science engineering, and early-stage venture development. Their technology may support research into rare brain disorders and neurodegenerative diseases.
How the platform works
The platform uses standardized human brain organoids as miniature tissue models. Automation monitors their structure, activity, and molecular responses before and after drug exposure. The data feeds predictive AI models for research into brain development, neurodegeneration, and healthy aging.
Vale Biolabs plans to advance collaborations with research and industry partners. The platform lets drug developers test treatments on human brain tissue earlier in development. This may reduce development costs and accelerate new therapies.